Microbot Medical Inc. (NASDAQ:MBOT) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Microbot Medical Inc. (NASDAQ:MBOT) have been given an average rating of “Moderate Buy” by the five brokerages that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $6.6250.

MBOT has been the subject of a number of analyst reports. Wall Street Zen raised shares of Microbot Medical from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Microbot Medical in a research note on Tuesday, April 14th. Loop Capital set a $4.00 price objective on shares of Microbot Medical in a research note on Wednesday, June 3rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Microbot Medical in a research note on Friday, April 10th.

Microbot Medical Price Performance

Shares of NASDAQ:MBOT opened at $1.78 on Monday. The company has a current ratio of 22.59, a quick ratio of 21.93 and a debt-to-equity ratio of 0.01. Microbot Medical has a 12 month low of $1.60 and a 12 month high of $4.67. The company has a 50-day moving average price of $2.07 and a 200 day moving average price of $2.18. The company has a market cap of $119.56 million, a price-to-earnings ratio of -6.85 and a beta of 1.04.

Microbot Medical (NASDAQ:MBOT) last announced its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.03. The business had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.30 million. As a group, equities research analysts predict that Microbot Medical will post -0.31 earnings per share for the current year.

Institutional Trading of Microbot Medical

Several institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Microbot Medical by 14.3% in the third quarter. Vanguard Group Inc. now owns 2,343,561 shares of the biotechnology company’s stock worth $7,148,000 after purchasing an additional 292,923 shares during the last quarter. CIBC Private Wealth Group LLC lifted its stake in Microbot Medical by 1.8% in the fourth quarter. CIBC Private Wealth Group LLC now owns 1,480,000 shares of the biotechnology company’s stock worth $2,960,000 after purchasing an additional 26,000 shares during the last quarter. CIBC Bancorp USA Inc. bought a new stake in Microbot Medical in the third quarter worth about $4,435,000. Heights Capital Management Inc. bought a new stake in Microbot Medical in the third quarter worth about $2,693,000. Finally, Geode Capital Management LLC lifted its stake in Microbot Medical by 54.4% in the fourth quarter. Geode Capital Management LLC now owns 761,995 shares of the biotechnology company’s stock worth $1,524,000 after purchasing an additional 268,609 shares during the last quarter. Institutional investors own 16.30% of the company’s stock.

Microbot Medical Company Profile

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.